Insulet (NASDAQ:PODD) Price Target Raised to $360.00

Insulet (NASDAQ:PODD) had its price target hoisted by Wells Fargo & Company from $350.00 to $360.00 in a research note issued to investors on Friday, Marketbeat Ratings reports. The brokerage currently has an overweight rating on the medical instruments supplier’s stock.

Other research analysts also recently issued research reports about the stock. Stifel Nicolaus assumed coverage on shares of Insulet in a research note on Tuesday, October 21st. They issued a “buy” rating and a $370.00 target price for the company. Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a research report on Wednesday, October 8th. Jefferies Financial Group lifted their target price on shares of Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday. Royal Bank Of Canada boosted their price target on Insulet from $350.00 to $365.00 and gave the company an “outperform” rating in a report on Friday, October 10th. Finally, Wolfe Research lifted their price objective on Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $371.38.

Insulet Price Performance

Shares of Insulet stock traded up $0.53 on Friday, hitting $320.35. The company’s stock had a trading volume of 544,810 shares, compared to its average volume of 719,407. The company has a market capitalization of $22.55 billion, a P/E ratio of 97.37, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. Insulet has a 52-week low of $230.05 and a 52-week high of $353.50. The firm has a fifty day moving average price of $325.06 and a 200-day moving average price of $310.30. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The company had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm’s quarterly revenue was up 29.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities research analysts expect that Insulet will post 3.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.39% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Insulet by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock worth $2,715,651,000 after buying an additional 87,845 shares during the period. Geode Capital Management LLC increased its position in shares of Insulet by 3.1% during the second quarter. Geode Capital Management LLC now owns 1,927,543 shares of the medical instruments supplier’s stock worth $603,211,000 after acquiring an additional 58,309 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Insulet by 34.8% in the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after acquiring an additional 297,734 shares in the last quarter. Groupama Asset Managment boosted its holdings in Insulet by 0.4% in the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock valued at $276,728,000 after purchasing an additional 3,759 shares during the last quarter. Finally, Norges Bank purchased a new position in Insulet in the second quarter valued at about $324,689,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.